Shilpa Medicare soars on getting USFDA nod for Capecitabine Tablets

13 Dec 2016 Evaluate

Shilpa Medicare is currently trading at Rs. 674.90, up by 14.45 points or 2.19% from its previous closing of Rs. 660.45 on the BSE.

The scrip opened at Rs. 656.30 and has touched a high and low of Rs. 677.85 and Rs. 645.30 respectively. So far 9931 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 686.00 on 28-Nov-2016 and a 52 week low of Rs. 355.00 on 20-Jan-2016.

Last one week high and low of the scrip stood at Rs. 680.00 and Rs. 622.25 respectively. The current market cap of the company is Rs. 5183.18 crore.

The promoters holding in the company stood at 56.89%, while Institutions and Non-Institutions held 15.35% and 27.76% respectively.

Shilpa Medicare has received an approval from the United States Food & Drug Administration (USFDA) (the Office of Bioequivalence) for Capecitabine Tablets USP, 150 mg and 500 mg to be bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Xeloda Tablets, 150 mg and 500 mg of Hoffmann-La Roche, Inc.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

911.00 -24.80 (-2.65%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.